Just over a month after it was approved in the UK, AstraZeneca and Ionis' Wainzua has been recommended for NHS use in the treatment of patients with polyneuropathy associated with transthyretin ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved eplontersen (Wainzua) to treat adults with polyneuropathy associated with hereditary transthyretin amyloidosis (ATTRv), ...

while new treatment Eplontersen (Wainzua) was accepted for the treatment of adults with a rare hereditary nerve condition called transthyretin-mediated amyloidosis (ATTRv amyloidosis). The first ...

while new treatment Eplontersen (Wainzua) was accepted for the treatment of adults with a rare hereditary nerve condition called transthyretin-mediated amyloidosis (ATTRv amyloidosis). The first ...

Sapablursen is currently being evaluated in adults living w The latest decision makes Ionis/AstraZeneca's Wainzua the only approved drug in the EU for ATTRv-PN that can be self-administered ...

Experiential digital technology, including immersive and interactive techniques like augmented reality, heralds significant potential for the pharma industry in offering new ways to interact with ...

The MHRA has approved eplontersen (Wainzua) for treating adults with polyneuropathy associated with hereditary transthyretin amyloidosis (ATTRv), a rare genetic condition caused by the transthyretin ...

New drug Bimekizumab (Bimzelx) was accepted for the treatment of adults with hidradenitis suppurativa, a long-term skin condition that causes abscesses and scarring on the skin, while new treatment ...